Brownstein Hyatt Farber Schreck is pleased to announce that Karla Arias has joined the firm’s Washington, D.C. office as of counsel in the Intellectual Property Department. She brings expertise in patent and trade secret litigation, as well as patent prosecution for clients in the chemical and pharmaceutical industries.
“Bringing Karla on board is a key step in our ongoing commitment to deepening our bench in high-stakes intellectual property matters,” said Airina Rodrigues, cochair of the firm’s IP Department. “Her unique combination of scientific rigor and legal insight will be an incredible asset to our clients, particularly those in the chemical and pharmaceutical sectors.”
Arias joins the firm from Crowell & Moring LLP, where she served as counsel in the Washington, D.C. office. Her extensive scientific background and legal acumen make her a valuable addition to the Brownstein team. Prior to her legal career, Arias was a postdoctoral fellow at Carnegie Mellon University, where she researched the degradation of endocrine-disrupting contaminants in water and the formation and reactivity of iron complexes.
She earned her doctorate in organic chemistry from the University of Zurich, focusing on the synthesis of supramolecular architectures and the study of fluorescent and phosphorescent properties of supramolecular building blocks. She also earned her J.D. from George Mason University and her bachelor’s degree from the University of California, San Diego.
TAGS:
CONTRIBUTORS:
Recent Insights
Read MoreFDA FY ’27 Budget Proposes Broad New Authorities and Reforms Across Food, Drugs and Medical Devices
Presentation | April 09, 2026Willful Infringement and Enhanced Damages, Current Trends to Inform your Damages Case
Client Alert | April 07, 2026Trump Admin Adjusts Tariffs for “Derivative Products” Containing Steel, Aluminum and Copper
Client Alert | April 03, 2026Critical Minerals Take Center Stage in Trump’s FY27 Budget Request
Client Alert | April 03, 2026Bulked-Up Defense, Slimmed-Down Domestic: Inside the FY 2027 Skinny Budget
Client Alert | April 03, 2026Trump Administration Announces Section 232 Tariffs on Pharmaceuticals
You have chosen to send an email to Brownstein Hyatt Farber Schreck or one of its lawyers. The sending and receipt of this email and the information in it does not in itself create and attorney-client relationship between us.
If you are not already a client, you should not provide us with information that you wish to have treated as privileged or confidential without first speaking to one of our lawyers.
If you provide information before we confirm that you are a client and that we are willing and able to represent you, we may not be required to treat that information as privileged, confidential, or protected information, and we may be able to represent a party adverse to you and even to use the information you submit to us against you.
I have read this and want to send an email.